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The p53 oncosuppressor is very seldom mutated in neuroblastoma, but several mecha-
nisms cooperate to its functional inactivation in this tumor. Increased MDM2 levels, due
to genetic ampliﬁcation or constitutive inhibition of p14ARF, signiﬁcantly contribute to this
event highlighting p53 reactivation as an attractive perspective for neuroblastoma treat-
ment. In addition to its role in tumorigenesis, MYCN sensitizes untransformed and cancer
cells to apoptosis. This is associated to a ﬁne modulation of the MDM2–p53 pathway.
Indeed MYCN induces p53 and MDM2 transcription, and, by evoking a DNA damage
response (DDR), it stabilizes p53 and its proapoptotic kinase Homeodomain Interacting
Protein Kinase 2 (HIPK2). Through the regulation of the HIPK2-p53 inhibitor High Mobil-
ity Group protein A1 (HMGA1) and the homeobox proteins BMI-1 and TWIST-1, MYCN
establishes a delicate balance between pro- and antiapoptotic molecules that might be
easily perturbed by a variety of insults, leading to cell death. MDM2–p53 antagonists,
such as Nutlin-3, are strikingly prone to inducing death in MYCN-ampliﬁed neuroblastoma,
by further pushing on HIPK2 accumulation. Here we discuss implications and caveats of
exploiting this pathway and its connections to MYCN-induced DDR for a tailored therapy
of MYCN-ampliﬁed neuroblastoma.
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Neuroblastoma, one of the most common tumor of child-
hood, is an extraordinary challenging nosocomial entity due to
its tremendous heterogeneous behavior ranging from sponta-
neous regression to very aggressive and inexorable progression. In
2009, the International Neuroblastoma Risk Group deﬁned seven
parameters (stage, age, histologic category, grade of tumor differ-
entiation, status of MYCNoncogene, chromosome 11q status, and
DNA ploidy) required to stratify neuroblastoma patients into ten-
tatively homogeneous risk groups and estimated that the high-risk
fraction (5-year event free survival <50%) accounted for about
40% of their 8800 patients (Cohn et al., 2009). About half of the
high-risk neuroblastoma patients are characterized by the MYCN
ampliﬁcation (MNA) status, which represents the most relevant
independent negative prognostic factor in neuroblastoma. Indeed
MNA occurs in about 20–25% of the cases and is most frequently
associated to treatment failure. Supporting its pivotal biological
role in neuroblastoma, MYCN overexpression in the neural crest
is sufﬁcient to promote the development of neuroblastic tumors
in transgenic mice (Weiss et al., 1997). Consistently, inhibition
of MYCN leads to death, differentiation, and/or impairment of
cell growth, suggesting that knocking it out in MYCN-addicted
tumors might represent a very effective strategy to cure this subset
of tumors. Unfortunately, however, efﬁcacious and immediately
translatable methods to deplete MYCN directly into a neurob-
lastoma patient are not yet available. While many groups are
looking for strategies aimed at directly targeting Myc (Soucek
et al., 2008; Hogarty and Maris, 2012), recent discoveries opened
the possibility to deliver target therapies forMNA tumors based on
synthetic lethal approaches (Molenaar et al., 2009; Cole et al., 2011)
or by enhancing the anti-cancer pathways intrinsically activated by
MYCN. Here we focus our attention on the p53-dependent apop-
totic pathway activated by MYCN as a potential target for the
treatment of MNA neuroblastoma.
THE ARF/MDM2/p53 PATHWAY IN NEUROBLASTOMA
p53 is amaster oncosuppressor protein involved in protecting cells
from genetic instability by inducing cell cycle arrest or apopto-
sis in response to cellular stress and DNA damage. Its genetic
inactivation characterizes more than 50% of human cancers and
its functional impairment occurs in most of the remaining part,
highlighting the“reactivation of p53”as a treatment option poten-
tially effective for an extremely broad range of human cancers.
Indeed, p53 restoration already proved to be effective in promot-
ing tumor regression in animalmodels and several strategies aimed
at restoring p53 function (i.e., p53 gene therapy, wild type p53
restoration via small molecole/MDM2-antagonists and mutant-
p53 folding restoration) are being currently tested in clinical trials
(Cheok et al., 2011).
p53 is very seldom mutated in childhood cancer of the cen-
tral and peripheral nervous system and in primary neuroblastoma
its mutation rate does not exceed 1–2% (Vogan et al., 1993). How-
ever,multiple hits seem to cooperate to p53 functional impairment
in this tumor. Its delocalization to the cytoplasm was initially
thought to contribute to p53 inactivation in neuroblastoma (Moll
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et al., 1996). However, the signiﬁcance of this ﬁnding is still
controversial, since others have shown p53 properly nuclear in
neuroblastoma cells. Moreover, p53 may also instruct cells to
undergo apoptosis by directly localizing at mitochondria and
its differential localization might inﬂuence the balance between
apoptosis and autophagy (Maiuri et al., 2010), whose outcome
might be rather important for the survival of a cancer cells. Thus,
extranuclear p53 should not be considered necessarily inactive and
the biological signiﬁcance of cytoplasmic p53 in neuroblastoma
deﬁnitely needs to be more thoroughly investigated.
Although p53 expression levels may be directly repressed by
miRNAs (Swarbrick et al., 2010), deregulation of the ARF/MDM2
pathway appears to be the most biologically relevant and the most
“druggable” target contributing to p53 functional inactivation in
neuroblastoma cells. The E3 ubiquitin ligase MDM2 is a master
regulator of p53 activity. Indeed it mediates p53 ubiquitination
and degradation, as well as cytoplasmic delocalization and tran-
scriptional inactivation. Disruption of MDM2–p53 interaction
physiologically occurs upon phosphorylation of p53 on serine 15
and serine 20 operated by the ATM and CHK2 kinases, respec-
tively, in response to several types of stress. MDM2 activity is
further controlled at multiple levels, including autoubiquitination
and degradation as well as by direct molecular interactions. In
example, by a direct binding to MDM2, p14ARF impairs its activ-
ity on p53. Interestingly, ARF inactivation (due to deletions or
promoter methylation) or MDM2 ampliﬁcation are frequently
found in neuroblastoma cell lines. Analysis of a small series
(41 cases) of neuroblastoma tumors documented ARF inacti-
vation or MDM2 ampliﬁcation at diagnosis in about 30% of
the cases, while ﬁve of six mutations detected on p53 were not
present in the primary lesion, but appeared at relapse or after
chemotherapy (Carr-Wilkinson et al., 2010). Although with the
limitation of the little statistical power, these data provide sup-
port to a number of observations: (i) p53 is only rarely mutated
in neuroblastoma (up to 15% after relapse and/or progression)
suggesting that neuroblastoma has “an innate requirement for
baseline p53 activity (perhaps to resist oncogenic stress)” as
stated by Kim and Shohet (2009). (ii) The ARF–MDM2 axis
is frequently hit in neuroblastoma cells via direct genetic and
epigenetic targeting, eventually resulting in high MDM2 activ-
ity. The increased expression of the homeobox proteins BMI-1
and TWIST-1 frequently occurring in neuroblastoma may fur-
ther contribute to this end (Valsesia-Wittmann et al., 2004; Ochiai
et al., 2010). (iii) Uncoupling p53 from its negative regulator
MDM2 with small molecules competing for the respective dock-
ing sites (such as Nutlin-3, MI-63, and RITA among others)
should lead to p53 reactivation, a potentially valuable approach
to neuroblastoma therapy. Indeed, Nutlin-3, a cis-imidazoline
small molecule that mimics a p53-binding peptide, interferes
with MDM2 binding to p53 and proved to be very effective to
reduce growth and eventually promote apoptosis in neuroblas-
toma cells (Barbieri et al., 2006; Van Maerken et al., 2006). Of
relevance, p53 reactivation via Nutlin-3 leads to cell cycle arrest
in non-cancer cells, which might help protecting them from the
adverse effects of chemotherapy, in the case of association ther-
apies. In an elegant preclinical study, Van Maerken et al. (2009)
showed that Nutlin-3 not only impairs neuroblastoma growth
in vitro, and in vivo, but also prevents tumor metastasis for-
mation in xenograft models. Interestingly, even vincristine- and
doxorubicin-resistant xenografts appeared strongly sensitive to
Nutlin-3, suggesting this approach does not suffer from cross-
resistance limitations, as long as the target cells have wild type
p53. A potential limitation to this strategy comes from the
observation that p53 reactivation via MDM2-antagonists such as
Nutlin-3 not necessarily cause apoptosis in cancer cells, but it may
also determine a transient growth inhibition depending on the
cell and molecular context (Rinaldo et al., 2009), with obvious
consequences on its possibility to eradicate cancer. Concerning
neuroblastoma, consistent data indicate that MNA cells are strik-
ingly sensitive to death induced by MDM2-antagonist, while cell
growth inhibition might be the preferential outcome in MYCN
single copy neuroblastoma (Figure 1). The emerging molecu-
lar picture providing a rationale for this is depicted in the next
paragraph.
THE APOPTOSIS-SENSITIVE PHENOTYPE INDUCED BY
MYCN AND THE MDM2–p53 PATHWAY: BENEFITS AND
CAVEATS OF p53 REACTIVATION STRATEGY
MYCN belongs to a conserved family of bHLHZip transcrip-
tion factors that coordinate cell proliferation, differentiation, and
survival as well as the interactions between cells and theirmicroen-
vironment, including angiogenesis, invasion, and inﬂammation.
Disruption of either c-Myc or N-Myc in mice leads to embry-
onic lethality due to growth defects in multiple organs and tissues.
Additionally, c-Myc is one of the four essential genetic ingredi-
ents that efﬁciently convert ﬁbroblast into pluripotent stem cells,
conﬁrming that Myc proteins play an unparalleled role in the
regulation of stemness and cell proliferation. Therefore it is not
surprising that direct or indirect deregulation of MYC expression
occurs in the vast majority of human cancers.
Primary deregulation of Myc expression or experimentally
induced Myc overexpression also leads to apoptosis, largely
(though not exclusively) via the ARF/p53 pathway, which initially
appeared paradoxical for a prototypic oncogene. However, more
recently it has been shown thatmany oncogenes (andmore in gen-
eral oncogenic stimuli unleashing unscheduled cell proliferation)
can trigger a DNA damage response (DDR) most likely connected
to the replication stress and certainly involving the signaling cas-
cades prompted by the ATM/ATR kinases, which in turn promote
p53 accumulation/activation and apoptosis, cell senescence or sta-
ble inhibition of cell cycle progression. The DDR, therefore, has
been envisaged as an intrinsic anti-cancer barrier that needs to be
disrupted (i.e., via inactivation of the ATM or p53) for cell trans-
formation to proceed (Bartkova et al., 2005; Gorgoulis et al., 2005;
Di Micco et al., 2006).
Although MYCN induces replication stress, DDR and genetic
instability in neuroblastoma cells (Petroni et al., 2011), p53 muta-
tions occur very rarely even in MNA neuroblastoma and p53
haploinsufﬁciency does not accelerate neuroblastoma develop-
ment in MYCN transgenic mice, consistent with a modulated
functional inactivation of p53 occurring in MNA neuroblastoma
(Weiss et al., 1997). Coherently, although MYCN overexpression
may induce apoptosis in cells from the nervous system, thiswas not
so frequently reported in neuroblastoma cells. Rather, it has long
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FIGURE 1 |The MDM2–p53 pathway, the apoptosis-sensitive phenotype
induced by MYCN and their modulation by Nutlin-3, in neuroblastoma
cells. p53 is rarely mutated in neuroblastoma. Rather, its inactivation
occurs at the functional level, mostly via increased MDM2 activity
(A). When p53 is uncoupled from MDM2 (by means of Nutlin-3) an
unmodiﬁed p53 accumulates in MYCN single copy cells, driving them
mostly into a reversible cell cycle arrest (B). MYCN overexpression and
MNA ampliﬁcation lead to dramatic changes in multiple components of the
MDM2–p53 pathways, modulating both pro- and antiapoptotic factors
in a coordinated fashion, which does not result in cell growth inhibition
or apoptosis, but rather in an apoptosis-sensitive phenotype, which
strongly depends on p53 and HIPK2 and can be easily recruited by
several sources of stress (C). In MNA cells, Nutlin-3 not only
uncouples p53 from the MDM2 inhibition, but also leads to strong
HIPK2 induction and consequently to commitment of p53 toward
apoptosis (D).
been recognized an apoptosis-sensitive phenotype that enhances
cell death in response to several sources of stress, including chemo-
toxic drugs, in MYCN overexpressing and MNA cells, in vitro
(Lutz et al., 1998; Fulda et al., 1999). This drug-sensitive phenotype
remains somehow paradoxical in light of the inexorable behavior
of MNA neuroblastoma, which relapse and progress very rapidly
(eventually after an initial remission) even despite very aggressive
therapies, in the majority of the cases.
Work from different labs, including ours, highlighted an entan-
gled molecular network governing the functional interactions
between MYCN and p53, which appears to be largely responsi-
ble for the well-known apoptosis-sensitive phenotype induced by
MYCN. As a matter of fact, MYCN favors p53 accumulation, by
directly promoting its transcription (Chen et al., 2010) but also
by increasing p53 serine 15 phosphorylation via a canonical DDR
(Petroni et al., 2011). Nevertheless, this does not end up with cell
growth inhibition (possibly due to impairment of the G1 cell cycle
checkpoint) neither it results in relevant cell death. How is p53
suppressed by MYCN? Slack et al. (2005) initially demonstrated
that MDM2 is a MYCN transcriptional target and postulated that
its increased expression could functionally limit p53 oncosuppres-
sive functions and thus allow tumorigenesis induced by MYCN.
Moreover, MYCN promotes the expression of the homeobox gene
BMI-1 (Ochiai et al., 2010), further pushingMDM2 activation, via
ARF suppression. MDM2, in turn, may facilitate MYCN expres-
sion by promoting its mRNA stabilization and translation (He
et al., 2011). Therefore multiple evidences seem to converge on
MDM2 being the main character in the story. Consistent with
these biochemical data, MDM2 deﬁciency suppresses MYCN-
dependent tumorigenesis in transgenic mice (Chen et al., 2009).
Of relevance, MYCN also induces the p53 proapoptotic home-
odomain interacting protein kinase 2 (HIPK2; Petroni et al., 2011).
HIPK2 binds and modulates p53 at multiple levels: it phospho-
rylates p53 on serine 46, a modiﬁcation required to commit p53
toward apoptotic target genes, and promotes CtBP degradation
thereby derepressing p53-dependent apoptotic targets such as Bax
and Noxa (Puca et al., 2010). HIPK2 is an unstable protein whose
levels are strictly controlled by the ubiquitin/proteasome system
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viamultiple E3ubiquitin ligases highly responsive to cellular stress.
Consequently, its degradation is suppressed in stressing conditions
and HIPK2 accumulates and may eventually elicit its apoptotic
potential. In example, upon DNA damage ATM/ATR kinases
phosphorylate the Siah-1 ubiquitin ligase loosening its afﬁnity
for HIPK2 and promoting its accumulation (Winter et al., 2008).
Coherent with this model, MYCN-induced DDR is responsible
for HIPK2 accumulation in MYCN overexpressing cells (Petroni
et al., 2011). HIPK2 and p53S46 phosphorylation are required
for the MYCN-dependent apoptosis-sensitive phenotype both in
MYCN overexpressing and in MNA cells (Petroni et al., 2011),
indicating that its proapoptotic function is recruited in these cells
upon additional stress. Under basal conditions, however, HIPK2
activity might be partially hampered by cytoplasmic sequestration
due to the increased expression of the High Mobility Group pro-
tein A1 (HMGA1), an additional transcriptional target of MYCN
(Giannini et al., 2005; Pierantoni et al., 2007). Therefore, MYCN
upregulates a series of molecules impinging on the MDM2–p53
pathway that create a delicate equilibrium between pro- and anti-
apoptotic factors. Incoming stress, such as exposure to chemotoxic
drugs, induces a reversible unbalance by increasing the stoichio-
metric weight of p53 and HIPK2, which accumulate, bringing up
apoptosis in a large number of cells (Figure 1), unless MDM2
increase due to p53 transcriptional activation restores the bal-
ance, progressively silencing the pathway. The MYCN-dependent
apoptotic-sensitive phenotype observed in vitro is mirrored in
vivo by a high level of mitosis-karyorrhexis and by the very fre-
quent initial response to the induction therapy observed in MNA
neuroblastoma patients. Nevertheless, MNA tumors most fre-
quently relapse, suggesting that several MNA cells ﬁnd the way
to escape apoptosis and are able to quickly reconstitute local
tumor bulk and distant metastatic dispersion. While the increase
in p53 mutation rate in relapsed and post-chemotherapy neurob-
lastoma indicates that inactivation of p53 is relevant for tumor
progression, the small amplitude of the phenomenon (up to 15%
mutation rate) conﬁrms that the power of the p53 pathway to
induce death under treatment is made functionally inefﬁcient,
at least in some cells. Thus, although the transient disequilib-
rium described above justiﬁes the increased rate of apoptosis in
MNA cells, it does not translate in a beneﬁt for the patients,
rather it pushes the selection of most resistant cancer clones. It
is reasonable to believe that a more potent and more permanent
unbalancing of the pathway leading to an increased activation
of the proapoptotic components (i.e., p53 and HIPK2) could
improve the outcome possibly also in vivo. Consistently, uncou-
pling p53 from MDM2, via small molecules MDM2-antagonists,
results in massive cell death in MNA neuroblastoma cells either
alone or in combined treatment with chemotoxic drugs (Gamble
et al., 2011; Petroni et al., 2011). Moreover, Nutlin-3 oral admin-
istration efﬁciently impaired tumor growth and metastatic spread
in xenograft models of MNA neuroblastoma (Van Maerken et al.,
2009). This enhanced power is likely to be due to its extra-activity
on HIPK2, which further accumulates upon treatment and is
strictly required for apoptosis to occur in MNA neuroblastoma
(Petroni et al., 2011). This is rather unexpected since accumu-
lated and Nutlin-3-bound MDM2 has been shown to maintain its
E3 ubiquitin ligase activity and to target HIPK2 for degradation,
preventing apoptotic activation of p53 and committing it toward
cell growth inhibition, which is a rather frequent outcome in non-
hematological cancer cells (Rinaldo et al., 2009). These ﬁndings
raised arguments that will need to be carefully addressed and
whose relevance is not necessarily restricted to neuroblastoma.
(a) Depending on the cell context, MDM2–p53 antagonists (such
as Nutlin-3) may have opposite effects on HIPK2 and this might
drive the biological outcome (i.e., cell growth inhibition versus
apoptosis) of p53 reactivation. (b) The molecular mechanisms
leading to HIPK2 induction by Nutlin-3 in MNA cells are cur-
rently unknown and a better understanding of this issue might
help identifying biomarkers predicting the biological outcome of
p53 reactivation, with obvious impact on the use of this drug
in cancer treatment. (c) The behavior of other p53 reactivating
molecules, such as MI-63, or RITA (that differs from the oth-
ers since it binds the p53 moiety) with respect to the balance
between MDM2, p53, and HIPK2 is currently unknown, but
there is reason to believe they might do different than Nutlin-
3, perhaps also depending on the cell/tumor context (Grinkevich
et al., 2009; Rinaldo et al., 2009). (d) Overall our current under-
standing of the molecular pathways modulating the biological
effects of p53 reactivation is rather poor and the expansion of this
area of investigation appears mandatory. In example, p53 might
promote apoptosis by direct localization at themitochondria inde-
pendent of its transcriptional activity and this function might
be also activated by Nutlin-3. Consistently, Galectin-3 (another
component of the p53 circuitry) impairs mitochondrial apopto-
sis in neuroblastoma and its repression by Nutlin-3 is required
for full-blown apoptosis in MNA cells (Veschi et al., 2012). Fur-
thermore, Nutlin-3 binds and inactivates also Bcl-2 and some
of its family members (Shin et al., 2012), with potentially p53-
independent effects on mitochondrial membrane permeability.
The role of p53 and its molecular circuitry at the mitochondria
has not been carefully ascertained in neuroblastoma cells, but fur-
ther investigation appears necessary for a better understanding of
the effects ofMDM2–p53 antagonists in neuroblastoma andmight
help identifying potential biomarkers (in addition to p53 muta-
tional status) to be used for a MDM2–p53 antagonists tailored
therapy.
While all of the above supports the hypothesis that the pharma-
cological reactivation of p53 might be an interesting therapeutic
opportunity for MNA neuroblastoma, that further improving
the molecular understanding of this pathway is also required
to avoid that an oversimpliﬁcation of the picture might cause
unforeseen effects in patients. The increasing levels of complex-
ity in the regulation of the pathway also call into play MDMX
as a relevant modulator of p53 mono- or polyubiquitination
by MDM2, which would alternatively cause its transcriptional
inhibition and nuclear export versus proteolytic degradation,
with relevant consequences on the biological outcome in nor-
mal and cancer cells (Wang and Jiang, 2012). Nutlin-3-bound
MDM2 was shown to retain several activities, including MDMX
E3 ubiquitin ligase activity, but the consequence of this in neu-
roblastoma are completely unexplored. Furthermore, MDM2
interacts with multiple partners and exploits oncogenic (but also
oncosuppressive) properties independent of p53 (Manfredi,2010).
Thus far, very little is known about how much these activities are
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conserved by Nutlin-3-bound MDM2 or by other MDM2–p53
antagonists. Thus, the possibility that unwanted activation of
MDM2 oncogenic properties could come together with p53 reac-
tivation should be seriously kept into account, unless speciﬁc
strategies to limit these potential side effects are designed.
Last, but not least, the inborn leaning to develop multi-
drug resistance brought about highly effective death-inducing
approaches in most aggressive tumors, should be considered.
Indeed, continuous exposure to Nutlin-3 promotes appearance
of de novo p53 mutations associated with a multi-drug-resistant
phenotype with an extremely high rate in several cancer cells,
including neuroblastoma (Michaelis et al., 2011). Together with
the notion that uncouplingMDM2–p53 interaction equally drives
stabilization of wild type and mutant-p53 proteins, this may rep-
resent a very major concern to the straightforward application
of MDM2-antagonists to cancer therapy, unless equally potent
p53-independent approaches are developed and tested in combi-
nation therapy. An interesting opportunity may be offered by the
high rate of replication stress of Myc-driven tumors (including
MNA neuroblastoma) and by their consequent high sensitivity to
inhibitors of ATR and CHK1 (Murga et al., 2011), two main signal
transducers in the DNA replication stress response. Importantly,
cell death induced by ATR or CHK1 inhibitors occurs indepen-
dent of p53, suggesting that reactivation of p53 and inhibition
of the replication stress response might trigger distinct cell death
pathways in Myc-driven tumors. Based on this, it appears possible
that the careful design of therapeutic strategies and administration
schedules aimed at attacking cancer cells on distinct, biologically
relevant pathways, such as DDR and ARF/MDM2/p53 circuitry,
might be highly effective and at the same time able to circum-
vent development of biological resistances in order to signiﬁcantly
contribute to defeat MNA neuroblastoma tumors.
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